Total submissions: 2
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV003086723 | SCV003481397 | uncertain significance | Primary dilated cardiomyopathy | 2022-05-21 | criteria provided, single submitter | clinical testing | This variant has not been reported in the literature in individuals affected with TXNRD2-related conditions. This variant is present in population databases (rs375498636, gnomAD 0.01%). Algorithms developed to predict the effect of missense changes on protein structure and function are either unavailable or do not agree on the potential impact of this missense change (SIFT: "Deleterious"; PolyPhen-2: "Probably Damaging"; Align-GVGD: "Class C0"). In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. This sequence change replaces isoleucine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 357 of the TXNRD2 protein (p.Ile357Thr). |
Ambry Genetics | RCV004073215 | SCV005024905 | uncertain significance | Cardiovascular phenotype | 2023-11-11 | criteria provided, single submitter | clinical testing | The p.I357T variant (also known as c.1070T>C), located in coding exon 12 of the TXNRD2 gene, results from a T to C substitution at nucleotide position 1070. The isoleucine at codon 357 is replaced by threonine, an amino acid with similar properties. This amino acid position is conserved. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |